The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

The Lung Cancer Research Foundation (LCRF) is pleased to announce the expansion of its Research Advocates. This select group ...

The Lung Cancer Research Foundation is expanding its research advocate groups. The group is made up of lung cancer patients ...

Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...

Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment.

With its clinically proven efficacy and safety profile, we believe IBTROZI has the potential to become a new standard for what targeted therapies can achieve in this type of lung cancer. With ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

While smoking is the leading cause of lung cancer it is not the only cause In fact many people develop lung cancer despite ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.